Moderna (MRNA) is up 3.6% to $58.30 ahead of the open after the FDA approved its mRNA-based seasonal flu vaccine, mFluvis, for adults ages 50+. The approval is a meaningful positive catalyst for revenue potential and supports near-term sentiment around the company’s vaccine pipeline.
Moderna (MRNA) is up 3.6% to $58.30 ahead of the open after the FDA approved its mRNA-based seasonal flu vaccine, mFluvis, for adults ages 50+. The approval is a meaningful positive catalyst for revenue potential and supports near-term sentiment around the company’s vaccine pipeline.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.70
Ticker Sentiment
